Following the US approval of company’s first drug for ALSthe co-founders and co-CEOs of Amylyx Pharmaceuticals Inc. are working with members of Congress on a bill that would change how reimbursement works for multidisciplinary ALS care centers.
Amylyx’s Justin Klee and Joshua Cohen have made amyotrophic lateral sclerosis their primary focus for the nine years their company has been in business. They got their first approval from the US Drug Administration last week, when the agency gave the green light to a drug intended to stop the neural degeneration that is a hallmark of the disease.
Klee and Cohen said they want to use their new platform to improve the patient experience, not only by selling the drug, but by removing other barriers to ALS care.
“Our #1 to 100 priorities are access,” Klee said.
One of these priorities will take the form of lobbying.
Cohen said his team is working with a consortium of ALS advocacy groups, leading doctors and members of Congress to adjust ALS billing codes so that multidisciplinary clinics are properly reimbursed for the services they receive. they provide. These clinics involve several types of doctors, including neuromuscular specialists, physiotherapists, occupational therapists, nurses, respiratory therapists, and speech therapists, as well as social workers who can help patients with various problems.